Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.53 -5.5%	$5.19	$3.79 ▼ $14.60	$277.07M	-0.92	1.45 million shs	1.10 million shs
CDTX Cidara Therapeutics	$22.06 +0.2%	$20.74	$10.14 ▼ $28.42	$272.02M	0.86	79,964 shs	116,386 shs
GLUE Monte Rosa Therapeutics	$4.14 -2.1%	$4.38	$3.21 ▼ $12.40	$254.65M	1.52	1.07 million shs	465,211 shs
LGST Semper Paratus Acquisition	$4.51	$4.52	$4.08 ▼ $12.03	$71.35M	-0.08	30,930 shs	12,596 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+1.84%	+4.73%	-30.09%	-37.87%
CDTX Cidara Therapeutics	0.00%	-9.14%	+1.71%	-4.30%	+73.84%
GLUE Monte Rosa Therapeutics	0.00%	+4.28%	-16.70%	-25.41%	+0.49%
LGST Semper Paratus Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	1.9791 of 5 stars	3.5	1.0	0.0	0.0	2.5	1.7	0.6
CDTX Cidara Therapeutics	4.2952 of 5 stars	4.6	3.0	0.0	4.6	2.1	0.8	0.0
GLUE Monte Rosa Therapeutics	2.0984 of 5 stars	3.4	0.0	0.0	0.0	2.6	3.3	0.6
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	279.75% Upside
CDTX Cidara Therapeutics	3.22	Buy	$41.86	89.74% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	274.40% Upside
LGST Semper Paratus Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LGST, CDTX, CADL, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
4/29/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$46.00 ➝ $46.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/10/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/21/2025	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $10.00
3/20/2025	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,308.91	N/A	N/A	$0.44 per share	12.57
CDTX Cidara Therapeutics	$302K	916.51	N/A	N/A	($1.82) per share	-12.12
GLUE Monte Rosa Therapeutics	$159.49M	1.60	N/A	N/A	$3.58 per share	1.16
LGST Semper Paratus Acquisition	N/A	N/A	$0.33 per share	13.74	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$37.94M	-$1.34	N/A	N/A	N/A	N/A	-629.29%	-173.39%	8/12/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/12/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
LGST Semper Paratus Acquisition	$4.41M	N/A	0.00	∞	N/A	N/A	-21.83%	3.10%	N/A

Latest LGST, CDTX, CADL, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	N/A	1.18	1.18
CDTX Cidara Therapeutics	N/A	3.54	3.54
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
LGST Semper Paratus Acquisition	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CDTX Cidara Therapeutics	35.82%
GLUE Monte Rosa Therapeutics	79.96%
LGST Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
CDTX Cidara Therapeutics	3.89%
GLUE Monte Rosa Therapeutics	6.90%
LGST Semper Paratus Acquisition	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	18.97 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
LGST Semper Paratus Acquisition	2,021	15.82 million	6.86 million	Not Optionable

LGST, CDTX, CADL, and GLUE Headlines

Recent News About These Companies

LGST.3850 Immigration Law (Formerly 41.385)

April 26, 2024 | uml.edu

LGST.3760 Family Law (Formerly 41.376)

March 27, 2024 | uml.edu

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

February 14, 2024 | finance.yahoo.com

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

February 14, 2024 | globenewswire.com

SPAC Semper Paratus shareholders okay merger with Tevogen Bio

February 1, 2024 | msn.com

Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio

February 1, 2024 | finance.yahoo.com

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

January 24, 2024 | finance.yahoo.com

Semper Paratus Acquisition Corp (LGST)

January 10, 2024 | investing.com

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

January 5, 2024 | finance.yahoo.com

With a 56% stake, Semper Paratus Acquisition Corporation (NASDAQ:LGST) insiders have a lot riding on the company

December 5, 2023 | finance.yahoo.com

Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement

September 29, 2023 | finance.yahoo.com

Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

September 14, 2023 | finance.yahoo.com

Tevogen to go public via merger with SPAC Semper Paratus

June 30, 2023 | msn.com

Biotech firm Tevogen Bio enters $1.2 bln SPAC deal for US listing

June 29, 2023 | reuters.com

Semper Paratus Acquisition Corp Class A

June 27, 2023 | morningstar.com

Semper Paratus Acquisition Corporation (LGST)

April 17, 2023 | finance.yahoo.com

Semper Paratus Acq Stock (NASDAQ:LGSTU), Trade Ideas

February 24, 2023 | benzinga.com

Semper Paratus Acquisition Corp. Cl A

January 25, 2023 | wsj.com

Saba Capital Management, L.P. Buys FTAC Zeus Acquisition Corp, Semper Paratus Acquisition Corp, ...

February 18, 2022 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGST, CDTX, CADL, and GLUE Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.53 -0.32 (-5.47%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.45 -0.08 (-1.45%)

As of 08:39 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cidara Therapeutics NASDAQ:CDTX

$22.06 +0.04 (+0.18%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.68 -0.38 (-1.72%)

As of 07:48 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.14 -0.09 (-2.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.18 +0.04 (+0.97%)

As of 08:00 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Semper Paratus Acquisition NASDAQ:LGST

Semper Paratus Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire companies operating in the transportation, supply chain, and logistics industries. Semper Paratus Acquisition Corporation was incorporated in 2021 and is based in New York, New York. Semper Paratus Acquisition Corporation operates as a subsidiary of Ssvk Associates, Llc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time